天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)
Instant ELISA Kit for Aspartate Aminotransferase (AST)
cCAT; AAT; ASAT; SGOT; GOT1; Cysteine transaminase, cytoplasmic; Transaminase A; Aspartate Transaminase 1,Cytoplasmic; Glutamic-Oxaloacetic Transaminase 1,Soluble
- 編號(hào)IEB214Mu
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)1h, 10min
- 檢測(cè)范圍1.56-100ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.55ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3448 ¥ 4926 ¥ 22167 ¥ 41871 ¥ 344820
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 79-96 | 86 |
EDTA plasma(n=5) | 85-99 | 90 |
heparin plasma(n=5) | 80-95 | 84 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 92-105% | 86-103% | 95-103% | 92-101% |
EDTA plasma(n=5) | 98-105% | 93-101% | 88-104% | 81-96% |
heparin plasma(n=5) | 87-101% | 80-99% | 83-98% | 80-89% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品及樣本)100µL,37°C溫育30分鐘;
3. 甩干,加檢測(cè)溶液A100µL,37°C溫育30分鐘;
4. 洗板3次;
5. 加檢測(cè)溶液B100µL, 37°C孵育10分鐘;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分鐘;
8. 加終止液50µL,立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本,其中的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標(biāo)記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色,并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值),計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB214Mu02 | 天冬氨酸轉(zhuǎn)氨酶(AST)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)活性蛋白 | Cell?culture;?Activity?Assays. |
PAB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體 | WB; IHC; ICC; IP. |
PAB214Mu02 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體 | WB; IHC; ICC; IP. |
LAB214Mu81 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
LAB214Mu71 | 天冬氨酸轉(zhuǎn)氨酶(AST)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
MAB214Mu22 | 天冬氨酸轉(zhuǎn)氨酶(AST)單克隆抗體 | WB; IHC; ICC; IP. |
MAB214Mu21 | 天冬氨酸轉(zhuǎn)氨酶(AST)單克隆抗體 | WB; IHC; ICC; IP. |
MEB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
IEB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB214Mu | 天冬氨酸轉(zhuǎn)氨酶(AST)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
PSB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSB214Mu01 | 天冬氨酸轉(zhuǎn)氨酶(AST)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Kidney International | Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms [PubMed: PMC3612362] |
Proceedings of the National Academy of Sciences | Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model [PubMed: PMC3382536] |
African Journal of Pharmacy and Pharmacology | Protective effect of Panax ginseng against N-acetyl-p-aminophenol-induced hepatotoxicity in rats [Academicjournals: Source] |
Kidney International | Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and-independent mechanisms [Pubmed: 23325074] |
European Journal of Pharmacology | Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats [ScienceDirect: S0014299914000235] |
Journal of Immunology | The P2X1 Receptor Is Required for Neutrophil Extravasation during Lipopolysaccharide-Induced Lethal Endotoxemia in Mice [Pubmed:25480563] |
Gastroenterol Res Pract | Assessing the Effect of Leptin on Liver Damage in Case of Hepatic Injury Associated with Paracetamol Poisoning [PubMed: 26697061] |
Gastroenterol Res Pract. | Advanced Studies in Clinical and Experimental Research in Gastroenterology [Pubmed:26955389] |
Scientific Reports | Adiponectin?protects?the?rats?liver?against?chronic?intermittent?hypoxia?induced?injury?throughAMP-activated?protein?kinase?pathway. [pubmed:27678302] |
?Biochimica et Biophysica Acta (BBA)-General Subjects | Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats [pubmed:28341485] |
Scientific Reports | Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency [Pubmed:29379059] |
FEBS?Open?Bio | A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis [Pubmed:29321963] |
BMC?Complementary and Alternative?Medicine? | Hepatoprotective activity of Erythrina× neillii leaf extract and characterization of its phytoconstituents [Pubmed: 28095910] |
laboratory investigation | Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency [Pubmed: 31186526] |
Brain Behavior and Immunity | Corticosterone-mediated microglia activation affects dendritic spine plasticity and motor learning functions in minimal hepatic encephalopathy [Pubmed: 31437533] |
Biomed Research International | Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet [Pubmed: 32149099] |
Nanomaterials | Biological Safety and Biodistribution of Chitosan Nanoparticles [Pubmed: 32340313] |
European Journal of Biology | Effects of Tempol in Lipopolysaccharide-Induced Liver Injury [] |
Pathogens | Antimalarial Effect of the Total Glycosides of the Medicinal Plant, Ranunculus japonicus [33925018] |
Int Immunopharmacol | Taraxasterol mitigates Con A-induced hepatitis in mice by suppressing interleukin-2 expression and its signaling in T lymphocytes [34848154] |
Acta Pharmacol Sin | NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury [34937917] |
J Magn Reson Imaging | Water Specific MRI T1 Mapping for Evaluating Liver Inflammation Activity Grades in Rats With Methionine‐Choline‐Deficient Diet‐Induced Nonalcoholic Fatty Liver?… [Pubmed:35212074] |
Medcomm | Blockade of mIL‐6R alleviated lipopolysaccharide‐induced systemic inflammatory response syndrome by suppressing NF‐κB‐mediated Ccl2 expression and?… [Pubmed:35548710] |
International Immunopharmacology | Dimethyl fumarate ameliorates autoimmune hepatitis in mice by blocking NLRP3 inflammasome activation [Pubmed:35605433] |